Setting the Stage From Diagnoses to Dimensions

Newswise — Philadelphia, PA, September 29, 2016The case-control method, where researchers compare patients with a particular disease to healthy control participants, has increased understanding of disease-related effects at a group level. However, psychiatric pathology complicates assumptions of the method – that the illness can be defined and that patients cleanly fit the definition. Although psychiatry has characterized different diagnoses, patients within a diagnosis vary widely and symptoms often overlap diagnostic labels.

To address this issue, the National Institute of Mental Health recently developed the Research Domain Criteria (RDoC), a new framework to move away from diagnostic categories in favor of linking symptom domains with biological systems. However, without a practical way to implement the criteria, psychiatric research studies continue to fit patients into predefined categories.

In a new study published in Biological Psychiatry, Andre Marquand, PhD, of the Donders Institute for Brain, Cognition and Behaviour in The Netherlands, and colleagues establish a new framework for studying psychiatric pathology without losing the heterogeneity of patients.

“In contrast to virtually all existing approaches, our approach does not require partitioning the cohort into groups,” said Marquand, explaining that it instead aims to chart variation across the entire population. They achieve this by mapping the relationship between biology and behavior in each participant.

Because variation associated with disease often overlaps normal variation, the new framework offers a way to map healthy variation and determine where a patient falls on that continuum. According to Marquand, this approach is similar to the way normative growth charts are used to map child development.

The researchers demonstrated their approach by mapping variation in the relationship between trait impulsivity and reward-related brain behavior, which targets core features of many psychiatric disorders, in 491 healthy participants. The analysis not only identified participants that deviated from the rest of the group, but could infer how each individual differed.

“This study exemplifies the power of understanding the range of normal variation when attempting to characterize psychiatric pathology,” said John Krystal, Editor of Biological Psychiatry.

“This approach enables us to move beyond the case–control framework and make statistical inferences in a way that matches the clinical view: where diseases in individual patients are recognized as deviations from a healthy pattern of functioning,” said Marquand. The researchers believe this new approach will become an instrumental tool to understand individual variation in many psychiatric disorders.

---

Notes for editorsThe article is "Understanding Heterogeneity in Clinical Cohorts Using Normative Models: Beyond Case-Control Studies," by Andre F. Marquand, Iead Rezek, Jan Buitelaar, and Christian F. Beckmann (doi:10.1016/j.biopsych.2015.12.023). It appears in Biological Psychiatry, volume 80, issue 7 (2016), published by Elsevier.

Copies of this paper are available to credentialed journalists upon request; please contact Rhiannon Bugno at +1 214 648 0880 or [email protected]. Journalists wishing to interview the authors may contact Andre F. Marquand at [email protected].

The authors’ affiliations, and disclosures of financial and conflicts of interests are available in the article.

John H. Krystal, M.D., is Chairman of the Department of Psychiatry at the Yale University School of Medicine, Chief of Psychiatry at Yale-New Haven Hospital, and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here.

About Biological Psychiatry Biological Psychiatry is the official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.

The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.

Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 5th out of 140 Psychiatry titles and 11th out of 256 Neurosciences titles in the Journal Citations Reports® published by Thomson Reuters. The 2015 Impact Factor score for Biological Psychiatry is 11.212.

About ElsevierElsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com

Media contactRhiannon BugnoEditorial Office, Biological Psychiatry+1 214 648 0880[email protected]